Immunoglobulin may benefit those with COVID vaccine-related blood clots
High doses of intravenous immunoglobulin (IVIG) in conjunction with an anticoagulant were associated with resolved vaccine-induced immune thrombotic thrombocytopenia (VITT) in three patients, according to a report yesterday in the New England Journal of Medicine.
VITT occurs when antibodies attack protein factor 4 (PF4), leading to blood clumping and clots.